The experimental lupus treatment being developed by Argos Therapeutics is showing promise in early stage clinical trials, but the questions remain whether it’s enough progress to attract interest from a ...
Read more
April 24, 2012 10:42 am by Frank Vinluan | 0 Comments
Immunotherapy company Argos Therapeutics, which last month withdrew plans for a $65 million initial public offering, has now secured a $25 million round of financing to start phase 3 clinical ...
Read more
March 7, 2012 10:33 am by Frank Vinluan | 0 Comments
Immunotherapy company Argos Therapeutics has pulled back on its plans for an initial public offering and leaves it needing to find another way to finance phase 3 clinical trials for ...
Read more
Immunotherapy company Argos Therapeutics has developed a new technology that could set it apart from other biotechnology cancer treatments — an approach that’s completely personalized to the patient and also ...
Read more
